- Conditions
- Non-small Cell Lung Cancer, Progression of Non-small Cell Lung Cancer, Non-small Cell Lung Cancer Recurrent
- Interventions
- Docetaxel, HyperAcute®-Lung Immunotherapy, Gemcitabine, Pemetrexed
- Drug · Biological
- Lead sponsor
- NewLink Genetics Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 135 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 24
- States / cities
- Santa Rosa, California • Stamford, Connecticut • Gainesville, Florida + 20 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 433–456
of 1,628
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Untreated Metastatic Pancreatic Ductal Adenocarcinoma
- Interventions
- Nivolumab, Albumin-bound paclitaxel, Paricalcitol, Cisplatin, Gemcitabine
- Drug
- Lead sponsor
- HonorHealth Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2024
- U.S. locations
- 1
- States / cities
- Scottsdale, Arizona
- Conditions
- Pancreatic Cancer
- Interventions
- INTENSITY MODULATED RADIOTHERAPY, Gemcitabine
- Radiation · Drug
- Lead sponsor
- University of Michigan Rogel Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2014
- U.S. locations
- 2
- States / cities
- Chicago, Illinois • Ann Arbor, Michigan
- Conditions
- Triple Negative Breast Neoplasms
- Interventions
- Sacituzumab tirumotecan, Pembrolizumab, Rescue Medication, Paclitaxel, Nab-paclitaxel, Gemcitabine, Carboplatin
- Biological · Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 39
- States / cities
- Mobile, Alabama • Chandler, Arizona • Duarte, California + 33 more
- Conditions
- Metastatic Pancreatic Ductal Adenocarcinoma, Pancreatic Ductal Adenocarcinoma
- Interventions
- 5-Fluorouracil, Oxaliplatin, Leucovorin, Irinotecan, Gemcitabine, Nab Paclitaxel, Circulating Tumor Deoxyribonucleic acid (ctDNA) Assay
- Drug · Diagnostic Test
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Solid Tumor
- Interventions
- OBT076, a CD205-directed antibody-drug conjugate
- Drug
- Lead sponsor
- Oxford BioTherapeutics Ltd
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 10
- States / cities
- Phoenix, Arizona • Los Angeles, California • Santa Monica, California + 7 more
- Conditions
- Pancreatic Neoplasms, Pancreatic Cancer
- Interventions
- Gemcitabine, Cisplatin
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 2
- States / cities
- Atlanta, Georgia
- Conditions
- Bladder Cancer
- Interventions
- Gemcitabine, Carboplatin, Panitumumab, radical cystectomy
- Drug · Procedure
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2013
- U.S. locations
- 5
- States / cities
- Basking Ridge, New Jersey • Commack, New York • New York, New York + 2 more
- Conditions
- Metastasis, Breast Cancer
- Interventions
- NKTR-102, Eribulin, Ixabepilone, Vinorelbine, Gemcitabine, Paclitaxel, Docetaxel, Nab-paclitaxel
- Drug
- Lead sponsor
- Nektar Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 178 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 19
- States / cities
- Tucson, Arizona • Orange, California • San Francisco, California + 16 more
- Conditions
- Resectable Stage IIA to IIIB Non-small Cell Lung Cancer
- Interventions
- Nivolumab, (8gy x 3), Platinum Doublet
- Drug · Radiation
- Lead sponsor
- Montefiore Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2030
- U.S. locations
- 4
- States / cities
- St Louis, Missouri • The Bronx, New York • White Plains, New York + 1 more
- Conditions
- Non-Muscle Invasive Bladder Urothelial Carcinoma, Recurrent Non-Muscle Invasive Bladder Urothelial Carcinoma, Stage I Bladder Cancer AJCC v8
- Interventions
- Biospecimen Collection, Cisplatin, Computed Tomography, Fluorouracil, Gemcitabine, Magnetic Resonance Imaging, Mitomycin, Pembrolizumab, Questionnaire Administration, Radiation Therapy
- Procedure · Drug · Biological + 2 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 145
- States / cities
- Tucson, Arizona • Fayetteville, Arkansas • Rogers, Arkansas + 103 more
- Conditions
- Borderline Resectable Pancreatic Adenocarcinoma, Resectable Pancreatic Adenocarcinoma, Stage IA Pancreatic Cancer AJCC v8, Stage IB Pancreatic Cancer AJCC v8, Stage IIA Pancreatic Cancer AJCC v8, Stage IIB Pancreatic Cancer AJCC v8
- Interventions
- Durvalumab, Gemcitabine, Nab-paclitaxel, Oleclumab
- Biological · Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Non Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma
- Interventions
- Mavrostobart (PT199), Tislelizumab, Gemcitabine + nab-Paclitaxel, Docetaxel, Pemetrexed, Gemcitabine, Carboplatin + Pemetrexed, Pembrolizumab + Carboplatin + Pemetrexed
- Drug
- Lead sponsor
- Phanes Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 6
- States / cities
- Huntersville, North Carolina • Oklahoma City, Oklahoma • Nashville, Tennessee + 3 more
- Conditions
- Bladder Cancer
- Interventions
- Cisplatin, Gemcitabine, Bevacizumab
- Drug
- Lead sponsor
- Christopher Sweeney, MBBS
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 11
- States / cities
- Chicago, Illinois • Galesburg, Illinois • Evansville, Indiana + 7 more
- Conditions
- Pancreatic Cancer
- Interventions
- Gemcitabine, Erlotinib, Sorafenib
- Drug
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2013
- U.S. locations
- 3
- States / cities
- Palm Springs, California • New York, New York
- Conditions
- Unresectable Intrahepatic Cholangiocarcinoma, Resectable Intrahepatic Cholangiocarcinoma
- Interventions
- Gemcitabine, Cisplatin, Surgery, Radiation
- Drug · Procedure · Radiation
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Bile Duct Cancer, Intrahepatic Cholangiocarcinoma
- Interventions
- Melphalan/HDS, Cisplatin and Gemcitabine
- Combination Product · Drug
- Lead sponsor
- Delcath Systems Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 295 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 3
- States / cities
- Durham, North Carolina • Columbus, Ohio • Memphis, Tennessee
- Conditions
- Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Interventions
- carboplatin, gemcitabine hydrochloride, paclitaxel
- Drug
- Lead sponsor
- Gynecologic Oncology Group
- Network
- Eligibility
- 18 Years to 80 Years · Female only
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1998
- U.S. locations
- 63
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 50 more
- Conditions
- Biliary Track Cancer
- Interventions
- Gemcitabine, Cisplatin, Durvalumab, Pembrolizumab, Histotripsy
- Drug · Device
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Cervical Cancer
- Interventions
- gemcitabine hydrochloride
- Drug
- Lead sponsor
- Gynecologic Oncology Group
- Network
- Eligibility
- 18 Years and older · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2000
- U.S. locations
- 38
- States / cities
- Birmingham, Alabama • Los Angeles, California • Los Gatos, California + 31 more
- Conditions
- Pancreatic Adenocarcinoma
- Interventions
- Milestone 1: Targeted chemotherapy prior to surgery, Milestone 2: Chemoradiotherapy (cXRT), Milestone 3: Targeted chemotherapy prior to surgery, Milestone 3: Chemoradiotherapy (cXRT), Milestone 4: standard FOLFIRINOX chemotherapy prior to surgery, Milestone 4: Chemoradiotherapy (cXRT), Milestone 5: Targeted chemotherapy after surgery, Milestone 5: Chemoradiotherapy (cXRT), Milestone 6: Gemcitabine after surgery, Milestone 6: Chemoradiotherapy (cXRT), Milestone 7: Chemoradiotherapy (cXRT), Milestone 8: Targeted chemotherapy after surgery, Milestone 9: Gemcitabine after surgery, Milestone 10: No additional therapy after surgery
- Drug · Radiation · Other
- Lead sponsor
- Medical College of Wisconsin
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 229 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2022
- U.S. locations
- 2
- States / cities
- Cincinnati, Ohio • Milwaukee, Wisconsin
- Conditions
- Pancreatic Cancer, Biliary Cancer
- Interventions
- gemcitabine, capecitabine
- Drug
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 2
- States / cities
- San Francisco, California • Salt Lake City, Utah
- Conditions
- Breast Cancer
- Interventions
- erlotinib hydrochloride, gemcitabine hydrochloride
- Drug
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2009
- U.S. locations
- 25
- States / cities
- Scottsdale, Arizona • Jacksonville, Florida • Peoria, Illinois + 22 more
- Conditions
- Biliary Cancer
- Interventions
- Gemcitabine, docetaxel, and capecitabine
- Drug
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2010
- U.S. locations
- 1
- States / cities
- New York, New York